Becton Dickinson Raises Investment In India
US company Becton Dickinson plans to raise its investment in India from $30 million to $100 million in five years.
Last year, Becton Dickinson India, a $2.7 billion health care company, set up a 100% subsidiary in India on an area covering 12.5 acres in the State of Haryana, 90 kilometers from Delhi. An automated plant at Bawal in Haryana is to become operational in 1997, the company said at a recent press conference in India.
The Indian plant will be the firm's fourth in the Asia-Pacific region after Japan, China and Singapore. Clateo Castellini, chairman and chief executive of the firm, said that India would become an important manufacturing center for the Asia-Pacific region.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze